Tweet
Drug Discovery & Development
<img alt="" height="1" width="1" />
FDA spurns Lilly, Boehringer diabetes drug, cites factory problems
Reuters
(Reuters) - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed problems at a facility where it would be made. The drugmakers, in a joint ...
FDA doesn't approve Lilly-Boehringer diabetes drugBusinessweek
Facility Concerns Kill Lilly-Boehringer Diabetes DrugPharmaceutical Processing
Lilly's Diabetes Pill Rejected by FDA Over ManufacturingBloomberg
FierceBiotech -Wall Street Journal -NASDAQ
all 22 news articles »
More...